Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial

Investigators conducted a randomized, double-blind, placebo-controlled, Phase III trial with 363 patients with asymptomatic, treatment-naïve, Binet stage A chronic lymphocytic leukemia at increased risk of progression to receive ibrutinib at a daily dose of 420 mg or placebo.